🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT03193567
Recruiting Phase 1

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

NCT03193567 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Phase 1
Started
2017-09-14
Last updated
2024-11-19

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

HEKT cell

HEKT cell: 3 cycles of HEKT cell treatment

Study summary

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female patients' age from 18 years to 70 years. * Patients who have a life expectancy of at least 3 months. * pathologically confirmed non-small cell lung cancer. * failed in previous standard chemotherapy and targeted therapy. * Karnofsky performance status 0-1. * adequate organ functions. Exclusion Criteria: * Pregnant and lactating women. * Patients with T cell lymphoma, syphilis, AIDS or combination * Patients with highly allergic or have a history of severe allergies * Patients with severe hepatic or renal dysfunction * Patients with severe autoimmune disease or who is being treated with immunosuppressive agents * Patients with severe infection not controlled or High fever * Patients with organ transplantation or waiting for organ transplantation. * Patients with brain metastasis * Patients with severe coagulopathy (e.g. hemophilia) * Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital Shanghai China Recruiting

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03193567 on ClinicalTrials.gov ↗ ← All trials in China